IL-38

None New top-line data from a global Phase 3 clinical trial of patients with generalized pustular psoriasis (GPP) flares show rapid clearance of pustulation, erythema and scaling through four weeks after a single dose of 750 mg intravenous (IV) imsidolimab. Imsidolimab is a humanized IgG4 monoclonal antibody that inhibits the function of the interleukin-36 receptor (IL-36R mAb), a signaling pathway within the immune system shown to be involved in the pathogenesis of inflammatory diseases, including GPP. More than half of patients (53.3 percent) who received a single dose of 750 mg IV imsidolimab achieved clear or almost clear skin (Generalized Pustular Psoriasis Physician Global Assessment (GPPPGA) 0/1) by four weeks after dosing, compared to 13.3% of patients on placebo (p=0.0131). Additionally, imsidolimab was well tolerated with no imsidolimab-related serious adverse events (AEs) or severe AEs reported through end of study. All AEs reported in imsidolimab-treated patients were mild or moderate and balanced across imsidolimab-treated vs. placebo patients, including a low incidence and no elevation of infections. Only one of 30 (3.3%) imsidolimab-treated patients had detectable anti-drug antibodies (ADA), which were non-neutralizing.  “GPP is an unpredictable and potentially life-threatening skin disease with systemic symptoms,” said Professor Hervé Bachelez, M.D., Ph.D., Hôpital Saint-Louis, Paris, one of the world’s leading experts on GPP. “Achieving positive top-line results utilizing the GPPPGA composite endpoint in this well conducted, randomized controlled, global trial, along with a compelling safety profile, represents the potential for a single dose of imsidolimab to predictably provide relief for patients living with this burdensome disease.” GPP is a rare but debilitating skin disease that can be life-threatening if left untreated. It develops when a person’s immune system is over-activated, which leads to inflammation. People living with GPP experience flares of swollen and often painful pustules, or blister-like sores, on their skin. While the severity of symptoms that people with GPP experience differs, the negative impact on quality of life is universal. Patients often wait years for an accurate diagnosis and even after they’re finally diagnosed, they continue to experience poor control of symptoms while on current treatment options.1 Understanding the pathophysiology of GPP and the role of the IL-36 pathway Targeting the IL-36 pathway has become of particular interest since its role as an underlying biological driver of GPP was discovered.2 IL-36 receptor (IL-36r) is a protein that helps to regulate, or turn on, the pathway. There are several different IL-36 proteins that work in harmony to ensure a balanced immune response.3 When the IL-36 pathway is stimulated or turned on, there is an increase in IL-36r signaling, causing inflammation. Skin cells known as keratinocytes grow and release proteins that attract white blood cells, which makes inflammation worse. This is the reason why people with GPP develop pustules on their skin.4 New top-line data from first study to use novel assessment of GPP severity The registration-enabling GEMINI-1 Phase 3 trial for imsidolimab is the first randomized, double-blind, placebo-controlled trial to use the composite endpoint of GPPPGA at Week 4 as its primary assessment. The GPPPGA assessment, representing a stringent and comprehensive characterization of disease severity, required satisfying an overall clinical response score of 0/1 (clear or almost clear) collectively across each GPP disease attribute, including pustulation, erythema and scaling. A total of 45 patients, 15 patients per arm, were enrolled across diverse global regions. Patients were randomized 1:1:1 to receive a single infusion of 750 mg IV imsidolimab, 300 mg IV imsidolimab or placebo at Day 0. Additionally, 66.7% (10/15) of placebo patients exited GEMINI-1 early, crossed-over to GEMINI-2 and were eligible to receive rescue therapy with a single dose of 750 mg IV imsidolimab. AnaptysBio, Inc., the company developing imsidolimab, plans to present comprehensive data from GEMINI-1 and top-line GEMINI-2 results at a medical meeting in H2 2024. Additionally, AnaptysBio anticipates filing a biologics license application (BLA) with the U.S. Food and Drug Administration by the third quarter of 2024. AnaptysBio intends to out-license imsidolimab in 2024 and reallocate the potential proceeds of a transaction to further invest in the broad development of its best-in-class immune cell modulators in autoimmune and inflammatory diseases. To find out more, visit them here.   1 Reisner DV, Johnsson FD, Kotowsky N, Brunette S. Impact of Generalized Pustular Psoriasis from the Perspective of People Living with the Condition: Results of an Online Survey. Am. J. Clin. Dermatol. 2022; 23(Suppl 1):65-71. doi: 10.1007/s40257-021-00663-y 2 Sugiura K. Role of Interleukin 36 in Generalised Pustular Psoriasis and Beyond. Dermatol. Ther. (Heidelb). 2022; 12(2): 315-328. 3 Boutet M-A, Bart G, Penhoat M, Amiaud J, et al. Distinct expression of interleukin (IL)‐36α, β and γ, their antagonist IL‐36Ra and IL‐38 in psoriasis, rheumatoid arthritis and Crohn's disease. Clin. Exp. Immunol. 2016; 184(2): 159-173. doi: 10.1111/cei.12761 4 Queen D, Ediriweera C and Liang L. Function and Regulation of IL-36 Signaling in Inflammatory Diseases and Cancer Development. Front. Cell Dev. Biol. 2019; 7: 317. doi: 10.3389/fcell.2019.00317

EXTON, Pa.--(BUSINESS WIRE)-- Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update. “We believe combining Immunome and Morphimmune’s technologies represents a major step in our long-term strategy of creating a preeminent oncology therapeutics company,” stated Purnanand Sarma, PhD, President and CEO of Immunome. “Targeted cancer therapies have made great strides in recent years, and the possible synergy between Morphimmune’s Targeted Effector Platform and Immunome’s proprietary Discovery Engine presents an opportunity to discover and develop truly novel therapies that can help cancer patients. We look forward to completing the merger by the end the year.” Highlights Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies. In June 2023, Immunome and Morphimmune, a private biotechnology company focused on developing targeted oncology therapeutics, announced that the two companies entered into a definitive merger agreement. The closing of the transaction is subject to customary closing conditions, including the effectiveness of the registration statement on Form S-4 to be filed by Immunome, and the receipt of required stockholder approvals from Immunome and Morphimmune stockholders. The combined company, which will operate as Immunome, will feature a synergistic platform expected to enable the development of best-in-class targeted cancer therapies across multiple modalities Clay B. Siegall, Ph.D., current Morphimmune President & CEO and former co-founder & CEO of Seagen, Inc., to serve as Chairman and CEO of combined company A concurrent $125 million private placement investment with leading institutional investors will support development of a combined pipeline expected to submit three investigational new drug applications (INDs) within 18 months of closing Immunome Published Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity. In May 2023, Immunome announced the publication of data highlighting efficacy of its preclinical IL-38 blocking antibody, titled “IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation,” in the peer-reviewed journal mAbs. The data in the article demonstrates that antibody-based targeting of IL-38 leads to activation of the immunostimulatory anti-tumor mechanisms within the tumor microenvironment in preclinical testing. Financial Highlights Collaboration Revenue: Collaboration Revenue from the Collaboration Agreement with AbbVie for the three months ended June 30, 2023 was $4.3 million. Research and development (R&D) expenses: R&D expenses for the three months ended June 30, 2023 were $5.7 million. General and administrative (G&A) expenses: G&A expenses for the three months ended June 30, 2023 were $4.2 million. Net loss: Net loss for the three months ended June 30, 2023 was $5.6 million, or $0.46 per share. Cash and cash equivalents: As of June 30, 2023, cash and cash equivalents totaled $38.4 million. About Immunome Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop antibody therapeutics to improve patient care. The company’s focus is on discovering and developing therapeutics in oncology internally and in collaboration with its partners. Immunome’s proprietary Discovery Engine identifies novel therapeutic antibodies and their targets through an unbiased interrogation of human memory B cells, highly educated components of the immune system, isolated from patients. Memory B cells are key elements in the human immune system response to disease as they produce specific, high-affinity antibodies that bind to cancer antigens or pathogens. Immunome’s Discovery Engine incorporates high-throughput screening to enable efficient, unbiased, broad, and deep functional evaluation of patient memory B cell repertoires to identify antibodies directed at novel targets. The functional data Immunome generates differentiates Immunome’s approach from those that use deep sequencing of B cells to identify dominant clones that are common within and across patients and assumes genomic dominance is a hallmark of therapeutic utility. For more information, visit . Forward-Looking Statements Cautionary Statement Regarding Forward-Looking Statements Certain statements contained in this communication regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). These include, but are not limited to, statements regarding the anticipated completion and effects of the proposed merger and private placement and related timing; the combined company’s planned clinical programs, including the timeline for filing of INDs and planned clinical trials; the potential of the combined company’s product candidates; the expected trading of the combined company’s stock on Nasdaq; management of the combined company; and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Immunome undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. We use words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA. Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, the outcome of any legal proceedings that may be instituted against Morphimmune or Immunome following the announcement of the merger; the inability to complete the merger, including due to the inability to concurrently close the merger and the private placement of common stock or due to failure to obtain approval of the stockholders of Immunome; delays in obtaining, adverse conditions contained in, or the inability to obtain necessary regulatory approvals or complete regular reviews required to complete the merger, if any; the inability to recognize the anticipated benefits of the merger, which may be affected by, among other things, competition, the ability of the combined company to grow and successfully execute on its business plan; costs related to the merger; changes in the applicable laws or regulations; the timing for achievement of milestones and the corresponding receipt of milestone payments; the possibility that the combined company may be adversely affected by other economic, business, and/or competitive factors; the risk that regulatory approvals for the combined company’s programs and product candidates are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the post-combination combined company or the expected benefits of the merger; the combined company’s ability to manage future growth; the combined company’s ability to manage clinical trials or studies; the risk that pre-clinical data may not be predictive of clinical data; the complexity of numerous regulatory and legal requirements that the combined company needs to comply with to operate its business; the reliance on the combined company’s management; the prior experience and successes of the combined company’s management team are not indicative of any future success; the dependence on the success of Morphimmune’s targeted effector platform and Immunome’s human memory B cell platform; the failure to obtain, adequately protect, maintain or enforce the combined company’s intellectual property rights; and other risks and uncertainties indicated from time to time described in Immunome’s Annual Report on Form 10-K for the year ended December 31, 2022, the Registration Statement, once available, relating to the merger, including those under “Risk Factors” therein, and in Immunome’s other filings with the SEC. Immunome cautions that the foregoing list of factors is not exclusive and not to place undue reliance upon any forward-looking statements which speak only as of the date made. Moreover, Morphimmune and Immunome operate in a very competitive and rapidly changing environment. New risks emerge from time to time. Except as required by law, Immunome undertakes no obligation to update publicly any forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in their expectations. Changes and Additional Information About the Proposed Merger and Where to Find It This communication is not intended to be, and is not, a substitute for the proxy statement or any other document that Immunome has filed or may the Securities and Exchange Commission (“SEC”) in connection with the proposed merger. In connection with the proposed merger, Immunome has filed a registration statement on Form S-4 (File No. 333-273792) (the “Registration Statement”) with the SEC that includes a proxy statement/prospectus of Immunome, that will be both the proxy statement to be distributed to holders of Immunome’s common stock in connection with its solicitation of proxies for the vote by Immunome’s stockholders with respect to the proposed merger and other matters as may be described in the Registration Statement, as well as the prospectus relating to the offer and sale of the securities to be issued in the proposed merger. The Registration Statement, including the proxy statement/prospectus contained therein, contains important information about the proposed merger and the other matters to be voted upon at a meeting of Immunome’s stockholders to be held to approve the proposed merger and other matters (the “Merger Special Meeting”). Immunome may also documents with the SEC regarding the proposed merger. Immunome stockholders and other interested persons are advised to read the Registration Statement, including the proxy statement/prospectus contained therein, as well as any amendments or supplements thereto, because they contain important information about the proposed merger. When available, the definitive proxy statement/prospectus will be mailed to Immunome stockholders as of a record date to be established for voting on the proposed merger and the other matters to be voted upon at the Merger Special Meeting. No Offer or Solicitation This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall neither constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom. Participants in the Solicitation Immunome, Morphimmune, and their respective directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies from Immunome’s stockholders with respect to the proposed merger. Information regarding the persons who may be deemed participants in the solicitation of proxies from Immunome’s stockholders in connection with the proposed merger are contained in the proxy statement/prospectus forming a part of the Registration Statement and will be contained in the definitive proxy statement/prospectus relating to the proposed merger, when available, which will be filed with the SEC. IMMUNOME, INC. Condensed Balance Sheets (In thousands, except share data) (unaudited) June 30, 2023 December 31, 2022 Assets Current assets: Cash and cash equivalents $ 38,416 $ 20,323 Prepaid expenses and other current assets 1,110 2,326 Total current assets 39,526 22,649 Property and equipment, net 1,203 681 Operating right-of-use asset, net 174 284 Restricted cash 100 100 Deferred offering costs 432 332 Total assets $ 41,435 $ 24,046 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 3,699 $ 2,400 Accrued expenses and other current liabilities 5,025 4,931 Deferred revenue, current 17,668 — Total current liabilities 26,392 7,331 Deferred revenue, non-current 5,705 — Other long-term liabilities — 62 Total liabilities 32,097 7,393 Commitments and contingencies (Note 7) Stockholders’ equity: Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding at June 30, 2023 and December 31, 2022, respectively — — Common stock, $0.0001 par value; 200,000,000 shares authorized; 12,200,433 and 12,128,843 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively 1 1 Additional paid-in capital 135,165 132,653 Accumulated deficit (125,828 ) (116,001 ) Total stockholders’ equity 9,338 16,653 Total liabilities and stockholders’ equity $ 41,435 $ 24,046 IMMUNOME, INC. Condensed Statements of Operations (In thousands, except share and per share data) (unaudited) Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Collaboration revenue $ 4,263 $ — $ 6,627 $ — Operating expenses: Research and development 5,716 5,717 9,629 13,795 General and administrative 4,320 3,209 7,242 6,785 Total operating expenses 10,036 8,926 16,871 20,580 Loss from operations (5,773 ) (8,926 ) (10,244 ) (20,580 ) Interest income 216 2 417 3 Net loss $ (5,557 ) $ (8,924 ) $ (9,827 ) $ (20,577 ) Per share information: Net loss per share of common stock, basic and diluted $ (0.46 ) $ (0.74 ) $ (0.81 ) $ (1.70 ) Weighted-average common shares outstanding, basic and diluted 12,197,801 12,127,385 12,190,182 12,125,156 IMMUNOME, INC. Condensed Statement of Cash Flows (In thousands) (unaudited) Six Months ended June 30, 2023 2022 Cash flows from operating activities: Net loss $ (9,827 ) $ (20,577 ) Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Depreciation and amortization 195 224 Amortization of right-of-use asset 110 33 Share-based compensation 2,257 2,637 Changes in operating assets and liabilities: Prepaid expenses and other assets 1,216 4,448 Accounts payable 1,276 2,182 Accrued expenses and other current liabilities (33 ) (3,342 ) Deferred revenue 23,373 — Other long-term liabilities (62 ) (41 ) Net cash provided by (used in) operating activities 18,505 (14,436 ) Cash flows from investing activities: Purchases of property and equipment (446 ) (176 ) Net cash used in investing activities (446 ) (176 ) Cash flows from financing activities: Proceeds from exercise of stock options — 32 Proceeds from issuance of common stock under ATM, net 34 — Net cash provided by financing activities 34 32 Net increase (decrease) in cash and cash equivalents and restricted cash 18,093 (14,580 ) Cash and cash equivalents and restricted cash at beginning of period 20,423 49,329 Cash and cash equivalents and restricted cash at end of period $ 38,516 $ 34,749 Supplemental disclosures of cash flow information: Issuance of common stock to certain board of directors in lieu of accrued compensation $ 221 $ — Deferred offering costs in accrued expenses and other current liabilities $ 100 $ — Property and equipment included in accounts payable $ 23 $ — Property and equipment included accrued expenses and other current liabilities $ 248 $ —

The combined company, which will operate as Immunome, will feature a synergistic platform expected to enable the development of best-in-class targeted cancer therapies across multiple modalities Clay B. Siegall, Ph.D., current Morphimmune President & CEO and former co-founder & CEO of Seagen, Inc., to serve as Chairman and CEO of combined company A concurrent $125 million private placement investment with leading institutional investors will support development of a combined pipeline expected to submit three investigational new drug applications (INDs) within 18 months of closing EXTON, Pa. and SEATTLE, June 29, 2023 /PRNewswire/ -- Immunome (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B-cell platform to discover and develop antibody therapeutics to improve patient care, and Morphimmune, a private biotechnology company focused on developing targeted oncology therapeutics, today announced that they have entered into a definitive merger agreement. The Boards of Directors of both companies have approved the all-stock transaction. The combined company, which will operate as Immunome and retain the same ticker symbol, will be headquartered in Seattle, WA and will maintain cost-efficient research lab facilities in Exton, PA and West Lafayette, IN. Clay B. Siegall, Ph.D., who was appointed CEO and President of Morphimmune earlier this year, will serve as the CEO, President, and Chairman of the Board of Directors of Immunome. Dr. Siegall previously served as the CEO and President of Seagen, Inc., which he co-founded in July 1997. Under his nearly 25 years of leadership, Seagen became an industry leader in ADC therapeutics, earned FDA approvals for four cancer therapies, and grew to over $2 billion in annual revenue. During his tenure, he raised well over $1 billion of financing for Seagen from public and private markets and oversaw the company's acquisition of Cascadian Therapeutics. In March of 2023, Pfizer, Inc. agreed to purchase Seagen for $43 billion. "Clay Siegall's track record of drug development and shareholder value creation is exceptional, and we are honored to have him serve as Chairman and CEO after the merger closes," said Michael Rapp, Immunome Board Chairman. "By building on the accomplishments of Purnanand Sarma and the Immunome team, Clay will be positioned to develop best-in-class targeted cancer therapies across multiple modalities." The companies also announced an oversubscribed private placement investment of $125 million with participation from Enavate Sciences, EcoR1 Capital, Redmile Group, Janus Henderson Investors, Avidity Partners, Woodline Partners LP, and other leading institutional investors. In connection with the PIPE, James P. Boylan, Chief Executive Officer of Enavate Sciences, will be appointed to the Board of Directors of Immunome. Both the merger and private placement are expected to close by the end of Q4 2023. The investment will be used to continue development of the lead assets in Immunome's combined pipeline, to continue to advance the company's platforms, and for general working capital purposes. The combined pipeline includes a novel anti-IL-38 mAb derived from Immunome's discovery engine, as well as a folate receptor-targeted TLR7 agonist (FA-TLR7a) and FAP-targeted radioligand (177Lu-FAP). The company expects to submit three INDs within 18 months following the closing, including the anti-IL-38 program, which is now slated for submission in Q1 2024. Additionally, the company will be well-positioned to explore opportunities for strategic in-licensing and further acquisitions. "This is the first step in establishing a preeminent oncology company," said Dr. Siegall. "Combining Morphimmune's Targeted Effector Platform with Immunome's Discovery Engine will enable us to pursue novel targets and modalities, unlocking substantial synergistic value." "Given the quality of our science, the expertise of our combined leadership team, and the strengthened cash position, I am extremely enthusiastic about our potential to reduce the suffering and loss of life caused by cancer." "We founded Morphimmune to realize the extraordinary potential of Professor Philip S. Low's scientific vision, which builds on decades of work at Purdue University. Our subsequent investments in the company, our engagement with Clay Siegall as CEO and now the anticipated merger are evidence of that potential," said Isaac Barchas, Morphimmune Founding Board Chairman and Research Bridge Partners Co-Founder and CEO. Barchas will serve on Immunome's Board of Directors following the merger. About the Proposed Transaction Immunome will acquire Morphimmune through a reverse subsidiary merger that is intended to be a tax-free reorganization. Stockholders of Morphimmune will receive common stock of Immunome based on a fixed exchange ratio applicable to the specific class and series of Morphimmune capital stock and outstanding options to acquire Morphimmune common stock will be assumed by Immunome. At the effective time of the merger, prior to giving effect to the private placement, securityholders of Immunome will own approximately 55% of the combined company and securityholders of Morphimmune will own approximately 45% of the combined company on a fully diluted basis, excluding out-of-the-money securities and the inducement grant to Dr. Siegall discussed below. The closing of the transaction is subject to customary closing conditions, including the effectiveness of the registration statement on Form S-4 to be filed by Immunome, and the receipt of required stockholder approvals from Immunome and Morphimmune stockholders. In conjunction with execution of the merger agreement, Dr. Siegall entered into an employment agreement with Immunome that will become effective upon closing. In connection with the entry into the employment agreement, the Immunome Board of Directors approved a stock option grant to Dr. Siegall as an inducement material to Dr. Siegall entering into employment with Immunome in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option provides for the purchase of up to 2,137,080 shares of Immunome common stock at a price of $5.91 per share, the closing price per share of Immunome common stock as reported by Nasdaq on June 28, 2023, the date of grant, and vests over four years, with 25 percent of the shares vesting on the first anniversary of closing of the merger, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to Dr. Siegall's continued employment with Immunome through the applicable vesting dates. Stockholders of Immunome holding approximately 20% of the voting stock of Immunome executed voting and support agreements pursuant to which they agreed to vote in favor of the issuance of shares in the merger and related matters and stockholders of Morphimmune holding approximately 70% of the voting stock of Morphimmune executed voting and support agreements pursuant to which they agreed to vote in favor of the adoption of the merger agreement and the merger and other related matters. Following the proposed merger, the board of directors of the combined company will be comprised of seven members: two selected by Morphimmune, who will initially be Dr. Siegall and Mr. Barchas; one selected by Immunome, who will initially be Philip Wagenheim; and four additional independent directors, to be mutually agreed, one of whom will initially be Mr. Boylan. Stifel is serving as financial advisor and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. is serving as legal counsel to Immunome. TD Cowen is serving as financial advisor and Cooley LLP is serving as legal counsel to Morphimmune. In connection with the private placement, TD Cowen and SVB Securities are serving as placement agents, and Wedbush Securities Inc. is serving as a strategic advisor. About Immunome Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop antibody therapeutics to improve patient care. The company's focus is on discovering and developing therapeutics in oncology internally and in collaboration with its partners. Immunome's proprietary Discovery Engine identifies novel therapeutic antibodies and their targets through an unbiased interrogation of human memory B cells, highly educated components of the immune system, isolated from patients. Memory B cells are key elements in the human immune system response to disease as they produce specific, high-affinity antibodies that bind to cancer antigens or pathogens. Immunome's Discovery Engine incorporates high-throughput screening to enable efficient, unbiased, broad, and deep functional evaluation of patient memory B cell repertoires to identify antibodies directed at novel targets. The functional data Immunome generates differentiates Immunome's approach from those that use deep sequencing of B cells to identify dominant clones that are common within and across patients and assumes genomic dominance is a hallmark of therapeutic utility. For more information, visit . About Morphimmune Morphimmune is a biotechnology company focused on developing targeted oncology therapeutics. The company's proprietary Targeted Effector platform selectively delivers payloads to diseased cells. The targeted approach reduces toxicity and increases efficacy of known effector molecules, ultimately improving outcomes for patients. Morphimmune was founded on the research of the company's scientific co-founder, Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. Dr. Low previously founded Endocyte, which Novartis acquired for $2.1 billion in 2018. He has published more than 500 articles and has over 700 patents/patents pending, in addition to being the founder of seven companies to commercialize these discoveries. For more information, visit . Changes and Additional Information About the Proposed Merger and Where to Find It This communication is not intended to be, and is not, a substitute for the proxy statement or any other document that Immunome has filed or may file with the Securities and Exchange Commission ("SEC") in connection with the proposed merger. In connection with the proposed merger, Immunome intends to file a registration statement on Form S-4 (the "Registration Statement") with the SEC that will include a proxy statement/prospectus of Immunome, that will be both the proxy statement to be distributed to holders of Immunome's common stock in connection with its solicitation of proxies for the vote by Immunome's stockholders with respect to the proposed merger and other matters as may be described in the Registration Statement, as well as the prospectus relating to the offer and sale of the securities to be issued in the proposed merger. The Registration Statement, including the proxy statement/prospectus contained therein, when it is filed and declared effective by the SEC, will contain important information about the proposed merger and the other matters to be voted upon at a meeting of Immunome's stockholders to be held to approve the proposed merger and other matters (the "Merger Special Meeting"). Immunome may also file other documents with the SEC regarding the proposed merger. Immunome stockholders and other interested persons are advised to read, when available, the Registration Statement, including the proxy statement/prospectus contained therein, as well as any amendments or supplements thereto, because they will contain important information about the proposed merger. When available, the definitive proxy statement/prospectus will be mailed to Immunome stockholders as of a record date to be established for voting on the proposed merger and the other matters to be voted upon at the Merger Special Meeting. Immunome's stockholders may obtain copies of the aforementioned documents and other documents filed by Immunome with the SEC, without charge, once available, at the SEC's web site at , on Immunome's website at or by contacting Immunome's Investor Relations via email at [email protected]. Cautionary Statement Regarding Forward-Looking Statements Certain statements contained in this communication regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). These include, but are not limited to, statements regarding the anticipated completion and effects of the proposed merger and private placement and related timing; the combined company's planned clinical programs, including the timeline for filing of INDs and planned clinical trials; the potential of the combined company's product candidates; the combined company's cash position; the expected trading of the combined company's stock on Nasdaq; management of the combined company; and other statements regarding management's intentions, plans, beliefs, expectations or forecasts for the future. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Immunome and Morphimmune undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. We use words such as "anticipates," "believes," "plans," "expects," "projects," "future," "intends," "may," "will," "should," "could," "estimates," "predicts," "potential," "continue," "guidance," and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA. Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, the outcome of any legal proceedings that may be instituted against Morphimmune or Immunome following the announcement of the merger; the inability to complete the merger, including due to the inability to concurrently close the merger and the private placement of common stock or due to failure to obtain approval of the stockholders of Immunome; delays in obtaining, adverse conditions contained in, or the inability to obtain necessary regulatory approvals or complete regular reviews required to complete the merger, if any; the inability to recognize the anticipated benefits of the merger, which may be affected by, among other things, competition, the ability of the combined company to grow and successfully execute on its business plan; costs related to the merger; changes in the applicable laws or regulations; the timing for achievement of milestones and the corresponding receipt of milestone payments; the possibility that the combined company may be adversely affected by other economic, business, and/or competitive factors; the risk that regulatory approvals for the combined company's programs and product candidates are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the post-combination combined company or the expected benefits of the merger; the combined company's ability to manage future growth; the combined company's ability to manage clinical trials or studies; the risk that pre-clinical data may not be predictive of clinical data; the complexity of numerous regulatory and legal requirements that the combined company needs to comply with to operate its business; the reliance on the combined company's management; the prior experience and successes of the combined company's management team are not indicative of any future success; the dependence on the success of Morphimmune's targeted effector platform and Immunome's human memory B cell platform; the failure to obtain, adequately protect, maintain or enforce the combined company's intellectual property rights; and other risks and uncertainties indicated from time to time described in Immunome's Annual Report on Form 10-K for the year ended December 31, 2022, the Registration Statement, once available, relating to the merger, including those under "Risk Factors" therein, and in Immunome's other filings with the SEC. Morphimmune and Immunome caution that the foregoing list of factors is not exclusive and not to place undue reliance upon any forward-looking statements which speak only as of the date made. Moreover, Morphimmune and Immunome operate in a very competitive and rapidly changing environment. New risks emerge from time to time. Except as required by law, neither Morphimmune nor Immunome undertakes any obligation to update publicly any forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in their expectations. No Offer or Solicitation This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall neither constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom. Participants in the Solicitation Immunome, Morphimmune, and their respective directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies from Immunome's stockholders with respect to the proposed merger. Information regarding the persons who may be deemed participants in the solicitation of proxies from Immunome's stockholders in connection with the proposed merger will be contained in the proxy statement/prospectus forming a part of the Registration Statement and the definitive proxy statement/prospectus relating to the proposed merger, when available, which will be filed with the SEC. Investor Contact Corleen Roche Chief Financial Officer [email protected] Media Contact Bob Knott Principal, Timbre Strategies [email protected] SOURCE MorphImmune, Inc.